Literature DB >> 23628987

Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.

M Yanagi1, R H Joho2, S A Southcott1, A A Shukla1, S Ghose1, C A Tamminga1.   

Abstract

Neuronal firing is a fundamental element of cerebral function; and, voltage-gated potassium (K(+)) channels regulate that firing through the repolarization of action potentials. Kv3-type channels (Kv3.1-Kv3.4) represent a family of voltage-gated K(+) channels that have fast-spiking properties. Kv3.1 channel subunits are predominantly localized to cortical parvalbumin (PV)-positive, inhibitory interneurons. The firing properties of these interneurons participate in establishing the normal gamma oscillations and synchrony of cortical neuronal populations, thought to be the signature of higher information processing in human brain. Schizophrenia (SZ) is associated with abnormalities in cortical gamma synchrony and in information processing, particularly with dysfunction in working memory and executive function. Here, we report the distribution of Kv3.1b and Kv3.2 protein in normal human brain, showing that Kv3.1b is limited to neocortical areas, whereas Kv3.2 is abundantly represented in neo- and subcortical regions. In SZ cases, levels of Kv3.1b protein are decreased in the neocortex, but only in cases without antipsychotic drug (APD) treatment; Kv3.1 levels are normal in antipsychotic-treated cases. Kv3.2 is not different in distribution or in level between normal and SZ cases, nor influenced by APD, in any region tested. The apparent increase in Kv3.1b protein levels by APDs in SZ neocortex was confirmed in laboratory rodents treated with chronic APDs. These findings show a decrease in Kv3.1b channel protein in SZ neocortex, a deficit that is restored by APDs. This alteration could be fundamentally involved in the cortical manifestations of SZ and in the therapeutic response to APDs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23628987     DOI: 10.1038/mp.2013.49

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  49 in total

1.  K(+) channel expression distinguishes subpopulations of parvalbumin- and somatostatin-containing neocortical interneurons.

Authors:  A Chow; A Erisir; C Farb; M S Nadal; A Ozaita; D Lau; E Welker; B Rudy
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

2.  Resilient RTN fast spiking in Kv3.1 null mice suggests redundancy in the action potential repolarization mechanism.

Authors:  Darrell M Porcello; Chi Shun Ho; Rolf H Joho; John R Huguenard
Journal:  J Neurophysiol       Date:  2002-03       Impact factor: 2.714

Review 3.  Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia.

Authors:  Kwang-Hyuk Lee; Leanne M Williams; Michael Breakspear; Evian Gordon
Journal:  Brain Res Brain Res Rev       Date:  2003-01

Review 4.  Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Brain Res Rev       Date:  2006-06-08

Review 5.  The gamma cycle.

Authors:  Pascal Fries; Danko Nikolić; Wolf Singer
Journal:  Trends Neurosci       Date:  2007-06-06       Impact factor: 13.837

6.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

7.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

8.  Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition.

Authors:  Lindsay Rutter; Frederick W Carver; Tom Holroyd; Sreenivasan Rajamoni Nadar; Judy Mitchell-Francis; Jose Apud; Daniel R Weinberger; Richard Coppola
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

9.  Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.

Authors:  Nikolaos Mellios; Hsien-Sung Huang; Stephen P Baker; Marzena Galdzicka; Edward Ginns; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2009-01-01       Impact factor: 13.382

Review 10.  Ether-a-go-go-related gene potassium channels: what's all the buzz about?

Authors:  Paul D Shepard; Carmen C Canavier; Edwin S Levitan
Journal:  Schizophr Bull       Date:  2007-09-28       Impact factor: 9.306

View more
  33 in total

1.  Distinct Physiological Maturation of Parvalbumin-Positive Neuron Subtypes in Mouse Prefrontal Cortex.

Authors:  Takeaki Miyamae; Kehui Chen; David A Lewis; Guillermo Gonzalez-Burgos
Journal:  J Neurosci       Date:  2017-04-13       Impact factor: 6.167

2.  Loss of Function of KCNC1 is associated with intellectual disability without seizures.

Authors:  Karine Poirier; Géraldine Viot; Laura Lombardi; Clémence Jauny; Pierre Billuart; Thierry Bienvenu
Journal:  Eur J Hum Genet       Date:  2017-02-01       Impact factor: 4.246

3.  Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers.

Authors:  Brett A Clementz; John A Sweeney; Jordan P Hamm; Elena I Ivleva; Lauren E Ethridge; Godfrey D Pearlson; Matcheri S Keshavan; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2015-12-07       Impact factor: 18.112

4.  Lower gene expression for KCNS3 potassium channel subunit in parvalbumin-containing neurons in the prefrontal cortex in schizophrenia.

Authors:  Danko Georgiev; Dominique Arion; John F Enwright; Mitsuru Kikuchi; Yoshio Minabe; John P Corradi; David A Lewis; Takanori Hashimoto
Journal:  Am J Psychiatry       Date:  2014-01       Impact factor: 18.112

5.  Potassium channel gene associations with joint processing speed and white matter impairments in schizophrenia.

Authors:  H A Bruce; P Kochunov; S A Paciga; C L Hyde; X Chen; Z Xie; B Zhang; H S Xi; P O'Donnell; C Whelan; C R Schubert; A Bellon; S A Ament; D K Shukla; X Du; L M Rowland; H O'Neill; L E Hong
Journal:  Genes Brain Behav       Date:  2017-03-13       Impact factor: 3.449

6.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 7.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

Review 8.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

9.  Psychosis subgroups differ in intrinsic neural activity but not task-specific processing.

Authors:  Matthew E Hudgens-Haney; Lauren E Ethridge; Jennifer E McDowell; Sarah K Keedy; Godfrey D Pearlson; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney; Brett A Clementz
Journal:  Schizophr Res       Date:  2017-08-24       Impact factor: 4.939

10.  Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator.

Authors:  Puja K Parekh; Michelle M Sidor; Andrea Gillman; Darius Becker-Krail; Letizia Bettelini; Roberto Arban; Giuseppe S Alvaro; Erika Zambello; Chiara Mutinelli; Yanhua Huang; Charles H Large; Colleen A McClung
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.